pFRT/lacZeo Vector
Product Image
Invitrogen™

pFRT/lacZeo Vector

pFRT/lacZeo and pFRT/lacZeo2 were constructed for establishing Flp-In™ Cell Lines that contain a single FRT site. Each vector includes a:•Read more
Have Questions?
Catalog NumberQuantity
V60152020 μg
Catalog number V601520
Price (EUR)
866,00
20 µg
Add to cart
Quantity:
20 μg
Price (EUR)
866,00
20 µg
Add to cart
pFRT/lacZeo and pFRT/lacZeo2 were constructed for establishing Flp-In™ Cell Lines that contain a single FRT site. Each vector includes a:

• FRT site for subsequent targeted integration of a Flp-In™ expression vector
Z-Zeocin™ fusion for selection of stable integrants with Zeocin™

These vectors differ in the SV40 promoter that drives expression of the lacZ-Zeocin™ fusion. pFRT/lacZeo2 contains a truncated version of the SV40 promoter. Use of this vector facilitates the isolation of clones that have integrated the vector near enhancer elements in the genome. Selection of stable clones using pFRT/lacZeo2 may allow easier isolation of clones that express a gene of interest at higher levels.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Constitutive or Inducible SystemConstitutive
Delivery TypeTransfection
For Use With (Application)Targeted Integration
Product TypeFlp-In System Expression Vector
Quantity20 μg
Reporter GeneBeta-Gal (lacZ)
Selection Agent (Eukaryotic)Zeocin™
VectorpFRT
Product LineFlp-In
PromoterSV40
Protein TagUntagged
Unit Size20 µg
Contents & Storage
20 μg of vector, either pFRT/lacZeo or pFRT/lacZeo2, is provided supercoiled and lyophilized. Store at -20°C once resuspended. Vectors are guaranteed stable for 6 months when properly stored.

Frequently asked questions (FAQs)

Do I need to include a consensus Kozak sequence when I clone my gene of interest into one of your mammalian expression vectors?

The consensus Kozak sequence is A/G NNATGG, where the ATG indicates the initiation codon. Point mutations in the nucleotides surrounding the ATG have been shown to modulate translation efficiency. Although we make a general recommendation to include a Kozak consensus sequence, the necessity depends on the gene of interest and often, the ATG alone may be sufficient for efficient translation initiation. The best advice is to keep the native start site found in the cDNA unless one knows that it is not functionally ideal. If concerned about expression, it is advisable to test two constructs, one with the native start site and the other with a consensus Kozak. In general, all expression vectors that have an N-terminal fusion will already have an initiation site for translation.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

Do I need to include a ribosomal binding site (RBS/Shine Dalgarno sequence) or Kozak sequence when I clone my gene of interest?

ATG is often sufficient for efficient translation initiation although it depends upon the gene of interest. The best advice is to keep the native start site found in the cDNA unless one knows that it is not functionally ideal. If concerned about expression, it is advisable to test two constructs, one with the native start site and the other with a Shine Dalgarno sequence/RBS or consensus Kozak sequence (ACCAUGG), as the case may be. In general, all expression vectors that have an N-terminal fusion will already have a RBS or initiation site for translation.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

Can you tell me the difference between a Shine-Dalgarno sequence and a Kozak sequence?

Prokaryotic mRNAs contain a Shine-Dalgarno sequence, also known as a ribosome binding site (RBS), which is composed of the polypurine sequence AGGAGG located just 5’ of the AUG initiation codon. This sequence allows the message to bind efficiently to the ribosome due to its complementarity with the 3’-end of the 16S rRNA. Similarly, eukaryotic (and specifically mammalian) mRNA also contains sequence information important for efficient translation. However, this sequence, termed a Kozak sequence, is not a true ribosome binding site, but rather a translation initiation enhancer. The Kozak consensus sequence is ACCAUGG, where AUG is the initiation codon. A purine (A/G) in position -3 has a dominant effect; with a pyrimidine (C/T) in position -3, translation becomes more sensitive to changes in positions -1, -2, and +4. Expression levels can be reduced up to 95% when the -3 position is changed from a purine to pyrimidine. The +4 position has less influence on expression levels where approximately 50% reduction is seen. See the following references:

- Kozak, M. (1986) Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44, 283-292.
- Kozak, M. (1987) At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mol. Biol. 196, 947-950.
- Kozak, M. (1987) An analysis of 5´-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15, 8125-8148.
- Kozak, M. (1989) The scanning model for translation: An update. J. Cell Biol. 108, 229-241.
- Kozak, M. (1990) Evaluation of the fidelity of initiation of translation in reticulocyte lysates from commercial sources. Nucleic Acids Res. 18, 2828.

Note: The optimal Kozak sequence for Drosophila differs slightly, and yeast do not follow this rule at all. See the following references:

- Romanos, M.A., Scorer, C.A., Clare, J.J. (1992) Foreign gene expression in yeast: a review. Yeast 8, 423-488.
- Cavaneer, D.R. (1987) Comparison of the consensus sequence flanking translational start sites in Drosophila and vertebrates. Nucleic Acids Res. 15, 1353-1361.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

I sequenced one of your vectors after PCR amplification and observed a difference from what is provided online (or in the manual). Should I be concerned?

Our vectors have not been completely sequenced. Your sequence data may differ when compared to what is provided. Known mutations that do not affect the function of the vector are annotated in public databases.

Are your vectors routinely sequenced?

No, our vectors are not routinely sequenced. Quality control and release criteria utilize other methods.